MEDX.SW stock plunged 16.26% intraday to CHF 9.53 on 27 Feb 2026 after Medmix published FY-2025 results that mixed weaker revenue with better margins. The move made medmix AG (SIX: MEDX.SW) one of Switzerland’s top losers during the session, with volume at 82,374 shares versus a 3-month average of 91,914. Investors reacted to a 7.4% revenue decline paired with a 90 basis-point margin improvement, while EPS remains negative at -0.14. We break down the earnings, valuation, technicals, Meyka AI grading, and where short-term support and targets sit.

Intraday price action and drivers

MEDX.SW stock fell from an open of CHF 9.80 to a day low of CHF 9.44 and last traded at CHF 9.53 on the SIX. The one-day decline of -16.26% follows the FY-2025 update and heavier selling volume of 82,374 shares. The stock’s 50-day average is CHF 11.44 and the 200-day average is CHF 10.66, highlighting the short-term weakness versus longer-term averages.

MEDX.SW stock: FY-2025 results and market reaction

Medmix reported FY-2025 revenue down about 7.4% while margins improved by 90 basis points, a contrast that confused investors and triggered the intraday drop. The company’s FY release on 26 Feb 2026 highlighted margin recovery even as demand softened across some end markets. Market commentary and local coverage noted the same mix of revenue pressure and margin progress (source) and (source).

Fundamentals and valuation

Medmix (MEDX.SW) trades at CHF 9.53 with a market cap of CHF 395,539,841 and shares outstanding 40,819,385. EPS is -0.14 and the trailing PE is -69.21, reflecting a loss. Price-to-sales is 0.84, price-to-book is 0.93, and free cash flow yield is 13.07%. Net debt to EBITDA sits near 3.39x, and interest coverage is 2.06x, underlining leverage sensitivity if margins worsen.

Technical read: oversold signals and key levels

Technicals show MEDX.SW stock is deeply oversold: RSI 21.90, CCI -407.84, and MACD histogram negative. Immediate support is the intraday low CHF 9.44 and the 52-week low CHF 8.18. Resistance cluster sits at the 50-day average CHF 11.44 and the 200-day average CHF 10.66. Low liquidity and a relVolume of 5.87 amplify moves.

Meyka AI rates MEDX.SW with a score out of 100

Meyka AI rates MEDX.SW with a score of 66.95/100 — Grade B, HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary score blends fundamentals and momentum, but it is not financial advice.

Meyka AI’s forecast model projects a 12-month level of CHF 10.86, a quarterly scenario at CHF 12.30, and a monthly reference at CHF 8.64. Versus the current CHF 9.53, the 12-month projection implies an upside of 13.99%. Forecasts are model-based projections and not guarantees.

Risks and sector context

Medmix sits in Industrials, Industrial – Machinery, where peers show steadier margins and higher PE multiples. The sector’s recent performance is mixed and average debt-to-equity sits above Medmix’s level. Key risks include cyclicality in dental and industrial end markets, EPS volatility, and a netDebt/EBITDA of 3.39x that raises refinancing and margin risks if sales remain weak.

Final Thoughts

MEDX.SW stock’s intraday fall to CHF 9.53 on 27 Feb 2026 reflects investor concern after FY-2025 revenue weakness despite margin improvement. Short-term momentum is negative and technicals show oversold readings, with immediate support at CHF 9.44 and a 52-week low at CHF 8.18. On valuation, the stock trades at P/S 0.84 and PB 0.93, with negative EPS and net debt pressure that keep risk elevated. Meyka AI’s forecast model projects a 12-month level of CHF 10.86, implying +13.99% from today, while a monthly reference sits at CHF 8.64. Use these figures as scenario markers: near-term downside to CHF 8.64 is plausible if sentiment remains weak, while recovery toward CHF 12.30 requires margin stability and top-line recovery. Our analysis combines the earnings update, technicals, and Meyka AI grading to frame both the risk and the selective opportunity for investors monitoring the Industrials space. For live updates and deeper data, see MEDX.SW on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.